Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Helen Lavretsky, MD, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00602290
First received: January 23, 2008
Last updated: March 12, 2013
Last verified: March 2013

January 23, 2008
March 12, 2013
February 2008
January 2013   (final data collection date for primary outcome measure)
Hamilton Depression Rating Scale (HDRS) scores [ Time Frame: Measured at Week 16 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00602290 on ClinicalTrials.gov Archive Site
Cognitive tests; quality of life, disability, and safety assessments; candidate genes; and drug levels [ Time Frame: Measured at Week 16 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Effectiveness of Methylphenidate in Improving Cognition and Function in Older Adults With Depression
The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients

This study will evaluate the safety and effectiveness of methylphenidate in improving cognition and function in older adults with depression.

Less than 50% of older adults with depression achieve remission and functional recovery in response to first-line antidepressant treatment. Most are left with significant residual symptoms, putting them at risk for illness relapse, frailty, and suicide. Improved understanding of the neurobiology of depression in older adults and mechanisms of treatment response may lead to better clinical management of depression. Methylphenidate (MPH) has long been used in the elderly and the medically ill to provide rapid improvement in depression, apathy, and fatigue. However, its potential beneficial effects on cognitive and functional outcomes in older adults with depression have not been studied. Combining MPH with the serotonergic antidepressant citalopram may result in better clinical outcomes than would using citalopram alone. This study will compare the safety and effectiveness of MPH combined with citalopram, MPH combined with placebo, and citalopram combined with placebo in improving thinking, memory, and speed of recovery in older adults with depression. The study will also evaluate selected dopamine- and serotonin-related gene relationships with mood, cognitive symptoms, and treatment response to MPH and citalopram.

Participation in this double-blind study will last 16 weeks. All potential participants will initially undergo comprehensive medical, neuropsychiatric, and cognitive assessments and genetic testing. These initial assessments will include questionnaires about depressive symptoms, a medical history, an electrocardiogram (ECG), and a blood draw for the genetic testing. Eligible participants will then be randomly assigned to one of three groups: MPH and citalopram, MPH and placebo, or citalopram and placebo. All participants will receive 16 weeks of treatment with their assigned medications. Study visits will occur weekly for the first 6 weeks of treatment and bi-weekly for the remainder of the study. During study visits, participants will undergo vital sign and weight measurements, answer questionnaires, and report any medication side effects. Blood will again be drawn at Visits 4 and 10, and the ECG will be repeated at Visit 10. Most initial assessments will be repeated on Visit 13, the last study visit. Participants will also be contacted weekly by phone throughout the study to answer questions on how they are feeling and any possible side effects.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Depression
  • Drug: Citalopram
    Citalopram dosage will be 10 to 40 mg a day. Participants will begin taking one 20-mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of citalopram until treatment completion.
    Other Name: Celexa
  • Drug: Methylphenidate (MPH)
    MPH dosage will be 5 to 30 mg a day. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 12 capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
    Other Name: Ritalin
  • Drug: Placebo
    Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 12 capsules twice per day. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
  • Active Comparator: 1
    Participants will take a combination of citalopram and methylphenidate for 16 weeks
    Interventions:
    • Drug: Citalopram
    • Drug: Methylphenidate (MPH)
  • Active Comparator: 2
    Participants will take a combination of citalopram and placebo for 16 weeks
    Interventions:
    • Drug: Citalopram
    • Drug: Placebo
  • Active Comparator: 3
    Participants will take a combination of methylphenidate and placebo for 16 weeks
    Interventions:
    • Drug: Methylphenidate (MPH)
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
181
February 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Meets DSM-IV criteria for major depressive disorder (recurrent and nonrecurrent course will be identified)
  • Score of 20 or higher on the 24-item HDRS at study entry
  • Score of 26 or higher on the Mini-Mental State Exam (MMSE)

Exclusion Criteria:

  • History of psychiatric illness or a substance abuse disorder other than unipolar depression, diagnosed prior to the onset of the first depressive episode
  • Presence of psychotic symptoms
  • Severe or acute medical illness (e.g., major surgery, metastatic cancer, stroke, heart attack) 6 months prior to study entry
  • Acute suicidal or violent behavior or history of suicide attempt within the year prior to study entry
  • Presence of delirium, neurodegenerative dementia, Parkinson's disease, or any other central nervous system (CNS) diseases
  • Toxic or metabolic abnormalities on laboratory examination
  • Medications taken or medical illnesses present that could account for depression
  • Active heart failure categorized as Class III or greater according to New York Heart Association criteria
  • Heart attack or crescendo angina within the 3 months prior to study entry
  • Symptomatic cardiac arrhythmias or symptomatic, hemodynamically significant mitral or aortic valvular disease
  • Resting heart rate less than 50 beats per minute and a corrected QT (QTc) interval greater than 0.45 seconds
  • Second or third degree atrioventricular block
  • Systolic blood pressure greater than 180 mmHg or less than 90 mmHg and diastolic blood pressure greater than 105 mmHg or less than 50 mmHg at study entry
  • Treated with depot neuroleptic therapy within 6 months prior to study entry
  • Treated with any neuroleptic, antidepressant, anxiolytic medication (other than lorazepam), or over-the-counter CNS-active medications used for treatment of depression (e.g, St. John's Wort, kava-kava, melatonin) within 2 weeks (4 weeks for fluoxetine or monoamine-oxidase inhibitors [MAOIs]) prior to the first administration of study medication
  • Known allergy to citalopram or MPH or history of ineffective treatment with citalopram or MPH for current depressive episode
  • Requires concomitant therapy with any prescription or over-the-counter medications that have potentially dangerous interactions with either citalopram or MPH
  • Requires electroconvulsive therapy (ECT) or received ECT within 3 months prior to study entry
  • Initiated psychotherapy within 3 months prior to study entry or will be initiating or terminating psychotherapy during the study
Both
60 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00602290
R01 MH077650, R01MH077650, DATR A4-GPX
Yes
Helen Lavretsky, MD, University of California, Los Angeles
University of California, Los Angeles
National Institute of Mental Health (NIMH)
Principal Investigator: Helen Lavretsky, MD University of California, Los Angeles
University of California, Los Angeles
March 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP